TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Na
Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

Teva Pharmaceuticals and Royalty Pharma announced a funding agreement worth up to $500 million to accelerate clinical development of TEV-'408, an anti-IL-15 antibody candidate for vitiligo treatment. The deal includes $75 million for Phase 2b funding with an option for an additional $425 million for Phase 3 development. TEV-'408 is currently in Phase 1b for vitiligo and Phase 2a for celiac disease, addressing a significant unmet medical need with limited current treatment options.

Insights
VYLD   neutral

Mentioned as launching tokenization initiatives without specific details about success or scale


TEVA   positive

Teva secured substantial funding ($500M) to accelerate development of a promising pipeline candidate, supporting its Pivot to Growth strategy. The partnership with a reputable funding partner and emerging positive Phase 1b data for an unmet medical need in vitiligo treatment represent significant strategic progress.